The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1

Kidney fibrosis and fibrogenesis significantly exacerbate chronic kidney disease (CKD) progression and are essential therapeutic targets. Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM). Several studies have demonstrated that BZM attenuates renal impairment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeniya, Moko, Mori, Takayasu, Yui, Naofumi, Nomura, Naohiro, Mandai, Shintaro, Isobe, Kiyoshi, Chiga, Motoko, Sohara, Eisei, Rai, Tatemitsu, Uchida, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638992/
https://www.ncbi.nlm.nih.gov/pubmed/29026167
http://dx.doi.org/10.1038/s41598-017-13486-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638992/
https://www.ncbi.nlm.nih.gov/pubmed/29026167
http://dx.doi.org/10.1038/s41598-017-13486-x

Ejemplares similares